MediWound Ltd. (NASDAQ:MDWD) Receives $33.50 Average Target Price from Analysts

MediWound Ltd. (NASDAQ:MDWD) has received an average rating of “Moderate Buy” from the six analysts that are covering the firm, MarketBeat reports. One analyst has rated the stock with a sell recommendation, one has assigned a hold recommendation and four have given a buy recommendation to the company. The average twelve-month price objective among brokerages that have covered the stock in the last year is $33.50.

MDWD has been the subject of several recent analyst reports. Zacks Research upgraded shares of MediWound from a “strong sell” rating to a “hold” rating in a research report on Tuesday, November 11th. Weiss Ratings reissued a “sell (d-)” rating on shares of MediWound in a research note on Wednesday, October 8th. Wall Street Zen raised shares of MediWound from a “sell” rating to a “hold” rating in a research report on Saturday, November 22nd. Finally, HC Wainwright restated a “buy” rating and issued a $36.00 target price (up previously from $31.00) on shares of MediWound in a research report on Friday, November 21st.

Hedge Funds Weigh In On MediWound

Several large investors have recently made changes to their positions in MDWD. Charles Schwab Investment Management Inc. boosted its position in shares of MediWound by 17.5% during the 1st quarter. Charles Schwab Investment Management Inc. now owns 22,468 shares of the biopharmaceutical company’s stock worth $349,000 after purchasing an additional 3,343 shares during the period. Deutsche Bank AG lifted its stake in MediWound by 2,255.2% during the first quarter. Deutsche Bank AG now owns 6,312 shares of the biopharmaceutical company’s stock worth $98,000 after purchasing an additional 6,044 shares in the last quarter. Nuveen LLC purchased a new position in shares of MediWound during the first quarter worth $168,000. Corebridge Financial Inc. grew its stake in shares of MediWound by 17.1% in the first quarter. Corebridge Financial Inc. now owns 4,559 shares of the biopharmaceutical company’s stock valued at $71,000 after buying an additional 665 shares in the last quarter. Finally, MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. raised its holdings in shares of MediWound by 22.4% in the 1st quarter. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. now owns 5,452 shares of the biopharmaceutical company’s stock valued at $85,000 after buying an additional 999 shares during the period. 46.83% of the stock is currently owned by institutional investors and hedge funds.

MediWound Stock Performance

NASDAQ MDWD opened at $18.79 on Wednesday. The stock’s fifty day moving average is $18.32 and its two-hundred day moving average is $18.47. The firm has a market capitalization of $208.38 million, a P/E ratio of -9.89 and a beta of 0.07. MediWound has a fifty-two week low of $14.14 and a fifty-two week high of $22.50.

MediWound (NASDAQ:MDWD) last issued its earnings results on Thursday, November 20th. The biopharmaceutical company reported ($0.24) earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of ($0.81) by $0.57. MediWound had a negative return on equity of 62.11% and a negative net margin of 98.43%.The business had revenue of $5.43 million during the quarter, compared to the consensus estimate of $6.56 million. As a group, sell-side analysts forecast that MediWound will post -2.66 EPS for the current year.

MediWound Company Profile

MediWound Ltd. (NASDAQ: MDWD) is a biopharmaceutical company headquartered in Yavne, Israel, specializing in the development and commercialization of innovative enzymatic therapies for burn and wound management. Since its establishment, the company has focused on advancing proteolytic enzyme technology to address critical needs in debridement and tissue repair. MediWound operates research and development facilities in Israel and maintains commercial offices in the United States to support its global market presence.

The company’s lead product, NexoBrid®, is an enzyme-based debriding agent designed to selectively remove burn eschar without harming viable tissue.